IDENTIFICATION AND EVALUATION OF PATIENTS AT RISK OF DEVELOPING CARDIOTOXICITY AFTER RECEIVING CHEMOTHERAPY FOR BREAST CANCER, LEUKEMIA OR LYMPHOMA

Registry ID: MHICC-2018-003
Source registry: HEALTH_CANADA
Status: Ongoing
Study type: INTERVENTIONAL
Sponsor: MONTREAL HEART INSTITUTE
Start date: 2023-01-13
Last update: 2020-07-29

Conditions

LEUKEMIA
LYMPHOMA
BREAST CANCER

Related clinical trials

68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
A PHASE III, MULTICENTRE, OPEN-LABEL, RANDOMISED STUDY EVALUATING THE EFFICACY AND SAFETY OF R-MINI-CHOP × 2 FOLLOWED BY AZD0486 VERSUS R-MINI-CHOP × 6 IN ELDERLY OR UNFIT PARTICIPANTS WITH NEWLY DIAGNOSED LARGE B-CELL LYMPHOMA (SOUNDTRACK-D2)
A PHASE IB/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6 INHIBITOR
A PHASE 3 OPEN-LABEL RANDOMIZED STUDY ASSESSING THE EFFICACY AND SAFETY OF RLY-2608 + FULVESTRANT VERSUS CAPIVASERTIB + FULVESTRANT AS TREATMENT FOR PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE OR PROGRESSION ON OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR

View on source registry